PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double‐blind, placebo‐controlled study

  title={PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double‐blind, placebo‐controlled study},
  author={W. W. Dinsmore and Michael Grant Wyllie},
  journal={BJU International},
To determine the effect of PSD502 applied topically 5 min before intercourse on the Index of Premature Ejaculation (IPE) and intravaginal ejaculatory latency time (IELT) of men with lifelong premature ejaculation (PE) defined according to the International Society of Sexual Medicine (ISSM) definition; secondary objectives were to evaluate the safety and tolerability of PSD502 in patients with PE, and their sexual partners. 

Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study.

In this study, PSD502 applied topically to the glans penis 5 minutes before intercourse showed significantly improved ejaculatory latency, ejaculatory control, sexual satisfaction and distress and was shown to be well tolerated by patients and partners.

Sexual dysfunction: Topical spray treatment for premature ejaculation

Assessments revealed notably greater improvements in perceived control, personal distress, and satisfaction with sexual intercourse for patients and partners in the PsD502 group compared with those in the placebo group.

Sexual dysfunction: Anesthetic spray improves premature ejaculation

A metered-dose aerosol spray containing lidocaine and prilocaine showed a 6.3-fold increase in intravaginal ejaculatory latency times, improved all patient-reported outcomes and had no serious adverse effects.

Premature ejaculation: treatment update

An overview of current accepted treatments and emerging agents for the use in PE is provided and a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations is placed.

Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment - topical versus systemic.

  • A. Morales
  • Psychology, Medicine
    Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • 2012
Evidence demonstrated that PSD502, dapoxetine and other SSRIs all significantly improve the symptoms of PE, and systemic use of SSRIS presents risks associated with the known pharmacology of this class.

Fortacin™ Spray for the Treatment of Premature Ejaculation

The metered-dose spray delivery system allows the desensitizing agents to be deposited in a dose-controlled, concentrated film onto the glans penis consequently reducing its sensitivity, translating into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation and orgasmic pleasure.

New Concepts in the Diagnosis and Treatment of Premature Ejaculation

Emerging medications and the ability to tailor treatments based on genetic information likely will change the paradigm of this disorder and how it will be treated by clinicians.

Medical therapy for premature ejaculation

Dapoxetine, which is a on-demand SSRI, is the only licensed drug for the treatment of PE, increasing IELT by a factor of 2.5 to 3 with limited and tolerable side effects.

Lidocaine/prilocaine spray for premature ejaculation

  • Dtb Cmecpd
  • Psychology, Biology
    Drug and Therapeutics Bulletin
  • 2017
The evidence for lidocaine/prilocaine spray and whether it has a role in the treatment of premature ejaculation is considered.



Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine

To assess the utility of perceived control over ejaculation (‘control’) in the evaluation of treatment benefit in men with premature ejaculation (PE), and to compare effects associated with a

Topical lidocaine–prilocaine spray for the treatment of premature ejaculation: a proof of concept study

Topical LP spray, applied to the glans penis 15 min before intercourse, prolongs ejaculation time significantly and improves sexual satisfaction in both men with PE and their partners.

A multinational population survey of intravaginal ejaculation latency time.

The distribution of the Intravaginal ejaculation latency time (IELT) in all the five countries was positively skewed, with a median IELT of 5.4 minutes but with differences between countries, which was significantly different from each of the other countries.

‘Up and coming’ treatments for premature ejaculation: progress towards an approved therapy

A number of emerging therapies in various stages of development that show potential for use in the treatment of PE are reviewed, which may prove to offer the most favourable risk: benefit profile as well as the flexibility to adapt to differing frequencies of sexual activity.

Self-reported premature ejaculation and aspects of sexual functioning and satisfaction.

PE was a common problem, was characterized by a lack of ejaculatory control, and was associated with significant effects on sexual functioning and satisfaction, and additional research on the sensitivity and specificity of these self-report questions should be pursued.

Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study

Dapoxetine has moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn, and further studies are necessary to draw final conclusions on the efficacy of this drug in PE.

TEMPE: Topical Eutectic-Like Mixture for Premature Ejaculation

The authors evaluate here the progress that has been made towards the reformulation of these local anaesthetic agents into a unique eutectic-like formulation for use as a desensitising agent in the treatment of premature ejaculation, as well as examining other potential uses for the spray.

Patient reported outcomes used in the assessment of premature ejaculation.